<?xml version="1.0" encoding="UTF-8"?>
<p>Nonischemic dilated cardiomyopathy (DCM) is the most frequent cause of advanced heart failure 
 <xref rid="sct312271-bib-0001" ref-type="ref">1</xref>. Disease progression in DCM affects both ventricles, and right ventricular (RV) dysfunction represents an important adverse prognostic factor 
 <xref rid="sct312271-bib-0002" ref-type="ref">2</xref>, 
 <xref rid="sct312271-bib-0003" ref-type="ref">3</xref>. Although several clinical trials have demonstrated that left ventricular dysfunction in DCM can be partially reversed by cell therapy 
 <xref rid="sct312271-bib-0004" ref-type="ref">4</xref>, 
 <xref rid="sct312271-bib-0005" ref-type="ref">5</xref>, 
 <xref rid="sct312271-bib-0006" ref-type="ref">6</xref>, 
 <xref rid="sct312271-bib-0007" ref-type="ref">7</xref>, no study to date investigated the effects of this approach on RV. Thus, the aim of the present study was to investigate the effects of transendocardial CD34
 <sup>+</sup> cell therapy on RV function in patients with DCM.
</p>
